NCT02346435 The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
| NCT ID | NCT02346435 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Kidney Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2009-01 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2009-01 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \<=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.
Eligibility Criteria
Inclusion Criteria: * Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months. * Age ≥ 18 and able to read, understand and sign informed consent. * Must be willing to adhere to the treatment algorithm and time constraints therein. Exclusion Criteria: * Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.
Contact & Investigator
Mohamad E Allaf, MD, MBA
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT02346435 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Kidney Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02346435 currently recruiting?
Yes, NCT02346435 is actively recruiting participants. Contact the research team at nsingla2@jhmi.edu for enrollment information.
Where is the NCT02346435 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT02346435 clinical trial?
NCT02346435 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Mohamad E Allaf, MD, MBA at Johns Hopkins University. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.